Ligand Pharmaceuticals’ Captisol-enabled, propylene glycol-free drug melphalan has met all the endpoints in a Phase II trial treating patients with multiple myeloma.
Developed by Higuchi Biosciences Center, Captisol is a patent-protected, chemically altered cyclodextrin.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Phase II study compared the safety, tolerability and pharmacokinetic profiles of an intravenous formulation of propylene glycol-free melphalan to the standard multiple myeloma treatment.
The Captisol-enabled drug will provide longer administration durations and slower infusion rates, enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.
The trial, conducted in partnership with The University of Kansas Cancer Center, is partially funded by the Kansas Bioscience Authority.
The company plans to begin the 60-patient pivotal trial to further evaluate the safety and efficacy of the drug candidate in 2012.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
